Pathogenetic features of formation of experimental preeclampsia-like condition
- 作者: Reznik V.A.1, Ivanov D.O.1, Bagrov A.Y.2, Ruhlyada N.N.1, Tapilskaya N.I.1
-
隶属关系:
- St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
- Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences
- 期: 卷 10, 编号 6 (2019)
- 页面: 27-33
- 栏目: Original studies
- URL: https://ogarev-online.ru/pediatr/article/view/21297
- DOI: https://doi.org/10.17816/PED10627-33
- ID: 21297
如何引用文章
详细
Objective. To study the pathogenesis of clinical and laboratory syndromes of preeclampsia-like condition and the possibility of influencing them through the introduction of specific antibodies to marinobufagenin.
Materials and methods. 36 pregnant rats were used in the experiment. 24 rats from 12 to 19 days of pregnancy were prescribed a 1,8% NaCl solution to simulate a preeclampsia-like condition. Subsequently, this sample was divided into 2 groups. In one group (12 animals, the second group), preimmune rabbit serum was administered intraperitoneally as an immune agent. In another group (12 animals, the third group), a single intraperitoneal administration of polyclonal anti-marinobufagenin antibodies was performed. After the antibody injection, a comprehensive clinical and laboratory evaluation was performed.
Results. Against the background of a hypersol diet, an increase in systolic blood pressure was found, as well as the concentration of marinobufagenin in blood plasma. The introduction of antibodies to marinobufagenin caused a decrease in blood pressure. In addition, the formation of a preeclampsia-like condition showed an increase in endoglin and sFlt1 in the placenta, as well as an increase in sFlt1, collagen-1 and a decrease in Fli-1 in the thoracic aorta. The appointment of antibodies to marinobufagenin led to an increase in the content of Fli-1 to the level in the control group.
Summary. In the formation of a preeclampsia-like condition, an increase in the level of marinobufagenin in blood plasma leads to an increase in the content of antiangiogenic factors in the placenta and in the thoracic aorta. Intraperitoneal administration of antibodies to marinobufagenin contributes to a significant increase in the content of Fli-1.
作者简介
Vitaly Reznik
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
编辑信件的主要联系方式.
Email: vitaliy-reznik@mail.ru
MD, PhD, Associate Professor, Head Physician on Obstetrics and Gynecology
俄罗斯联邦, Saint PetersburgDmitry Ivanov
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Email: doivanov@yandex.ru
MD, PhD, Dr Med Sci, Professor, Rector
俄罗斯联邦, Saint PetersburgAleksej Bagrov
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences
Email: aybagrov@gmail.com
MD, PhD, Dr Med Sci, Senior Researcher
俄罗斯联邦, Saint PetersburgNikolaj Ruhlyada
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Email: nicolasr@mail.ru
MD, PhD, Dr Med Sci, Professor, Head, Department of Obstetrics and Gynecology
俄罗斯联邦, Saint PetersburgNatal’ya Tapilskaya
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Email: tapnatalia@yandex.ru
MD, PhD, Dr Med Sci, Professor Department of Obstetrics and Gynecology
俄罗斯联邦, Saint Petersburg参考
- Аверина И.В. Значение некоторых ферментных систем при физиологической беременности и преэклампсии // Педиатр. – 2011. – Т. 2. – № 4. – С. 12–15. [Averina IV. The role of some en zyme systems in normal pregnancy and pregnancy with preclamp sIA. Pediatrician (St. Petersburg). 2011;2(4):12-15. (In Russ.)]
- Григорова Ю.Н. Маринобуфагенин-индуцированный фиброз сосудистой стенки и возможности его коррекции: Автореф. дис. … канд. мед. наук. – СПб., 2017. [Grigorova YuN. Marinobufagenin-indutsirovannyy fibroz sosudistoy stenki i vozmozhnosti ego korrektsii. [dissertation] Saint Petersburg; 2017. (In Russ.)]
- Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-137. doi: 10.1053/j.semperi.2009.02.010.
- Fedorova OV, Agalakova NI, Talan MI, et al. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. J Hypertens. 2005;23(8):1515-1523. doi: 10.1097/01.hjh.0000174969.79836.8b.
- Fedorova OV, Simbirtsev AS, Kolodkin NI, et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens. 2008;26(12):2414-2425. doi: 10.1097/HJH.0b013e328312c86a.
- Fedorova OV, Zernetkina VI, Shilova VY, et al. Synthesis of an Endogenous Steroidal Na Pump Inhibitor Marinobufagenin, Implicated in Human Cardiovascular Diseases, Is Initiated by CYP27A1 via Bile Acid Pathway. Circ Cardiovasc Genet. 2015;8(5):736-745. doi: 10.1161/CIRCGENETICS.115.001217.
- Fedorova OV, Ishkaraeva VV, Grigorova YN, et al. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia. Int J Mol Sci. 2018;19(8). doi: 10.3390/ijms19082377.
- Jamison J, Lauffenburger D, Wang JC, Wells A. PKCdelta localization at the membrane increases matrix traction force dependent on PLCgamma1/EGFR signaling. PLoS One. 2013;8(10):e77434. doi: 10.1371/journal.pone.0077434.
- Lopatin DA, Ailamazian EK, Dmitrieva RI, et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens. 1999;17(8):1179-1187. doi: 10.1097/00004872-199917080-00018.
- Saleem S, McClure EM, Goudar SS, et al. A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. Bull World Health Organ. 2014;92(8):605-612. doi: 10.2471/BLT.13.127464.
- Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-e333. doi: 10.1016/s2214-109x(14)70227-x.
- Nikitina ER, Mikhailov AV, Nikandrova ES, et al. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries. J Hypertens. 2011;29(4):769-776. doi: 10.1097/HJH.0b013e32834436a7.
- Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-799. doi: 10.1016/S0140-6736(05)17987-2.
- Sones JL, Davisson RL. Preeclampsia, of mice and women. Physiol Genomics. 2016;48(8):565-572. doi: 10.1152/physiolgenomics.00125.2015.
- Wu P, van den Berg C, Alfirevic Z, et al. Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2015;16(9):23035-23056. doi: 10.3390/ijms160923035.
- Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173-192. doi: 10.1146/annurev-pathol-121808-102149.
补充文件
